Blood test could personalize melanoma treatment, study hopes
NCT ID NCT07504796
First seen Apr 02, 2026 · Last updated Jun 15, 2026 · Updated 8 times
Summary
This study tests whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) to a two-drug combination (nivolumab and relatlimab) for people with advanced melanoma. About 90 adults with metastatic or advanced melanoma will take part. The goal is to see if this personalized approach improves how long the cancer stays under control while managing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.